U.S. Industrials Stock News

NasdaqGS:DIOD
NasdaqGS:DIODSemiconductor

Diodes (DIOD) Is Up 20.7% After Strong Q4 Results, Buybacks And Upbeat Q1 2026 Guidance

In February 2026, Diodes Incorporated reported fourth-quarter 2025 results showing higher sales and earnings year-over-year, outlined full-year growth in revenue and net income, completed a share repurchase of 720,485 shares for US$33.81 million, and issued first-quarter 2026 revenue guidance of about US$395 million, plus or minus 3%, indicating better-than-usual seasonality. Management also introduced three-year interim financial targets, including aspiring to reach US$2 billion in annual...
NasdaqGS:NBIX
NasdaqGS:NBIXBiotechs

Neurocrine Biosciences Enters New Growth Phase With Broader Revenue Mix

Neurocrine Biosciences (NasdaqGS:NBIX) is rolling out new products, including Chronesity and CRENESSITY, alongside a broad set of pipeline updates. The company reports strong early adoption for both launches, with CRENESSITY expected to reach blockbuster levels over time. Late stage clinical programs in neuropsychiatry and metabolic diseases are expanding, supported by a build out of the sales force and commercial capabilities. For you as an investor, the key point is that Neurocrine...
NasdaqGM:PSNY
NasdaqGM:PSNYAuto

A Look At Polestar Automotive Holding UK (NasdaqGM:PSNY) Valuation After Its US$400m Private Placement Announcement

Private placement draws fresh attention to Polestar Automotive Holding UK (NasdaqGM:PSNY) Polestar Automotive Holding UK (NasdaqGM:PSNY) has agreed to a private placement of over 20,682,000 new Class A American Depositary Shares, raising about US$400m from entities linked to Sumitomo Mitsui Banking Corporation and Standard Chartered. The deal is priced at US$19.34 per share and is expected to close by February 5, 2026. It brings in institutional capital while keeping each new investor below a...
NYSE:CRL
NYSE:CRLLife Sciences

Charles River Labs Quarterly Resilience Faces Declining Organic Revenue Test

Charles River Laboratories International (NYSE:CRL) has reported resilient quarterly results, with recent figures holding up despite pressures in its core operations. The company is working through a decline in organic revenue and facing ongoing challenges in its key business lines. Analysts expect only modest revenue growth ahead, while return on invested capital is trending lower, pointing to fewer highly profitable projects. For investors tracking NYSE:CRL, the share price of $158.74...